O	0	10	Endosialin	Endosialin	NN	B-NP
O	10	11	/	/	SYM	O
O	11	14	TEM	TEM	NN	B-NP
O	15	16	1	1	CD	I-NP
O	16	17	/	/	SYM	I-NP
O	17	22	CD248	CD248	NN	I-NP
O	23	25	is	be	VBZ	B-VP
O	26	27	a	a	DT	B-NP
B-Cell	28	36	pericyte	pericyte	NN	I-NP
O	37	43	marker	marker	NN	I-NP
O	44	46	of	of	IN	B-PP
B-Developing_anatomical_structure	47	56	embryonic	embryonic	JJ	B-NP
O	57	60	and	and	CC	I-NP
B-Cancer	61	66	tumor	tumor	NN	I-NP
O	67	85	neovascularization	neovascularization	NN	I-NP
O	85	86	.	.	.	O

O	87	90	The	The	DT	B-NP
O	91	100	formation	formation	NN	I-NP
O	101	103	of	of	IN	B-PP
O	104	114	functional	functional	JJ	B-NP
O	114	115	,	,	,	I-NP
O	116	122	mature	mature	JJ	I-NP
B-Multi-tissue_structure	123	128	blood	blood	NN	I-NP
I-Multi-tissue_structure	129	136	vessels	vessel	NNS	I-NP
O	137	144	depends	depend	VBZ	B-VP
O	145	147	on	on	IN	B-PP
O	148	151	the	the	DT	B-NP
O	152	163	interaction	interaction	NN	I-NP
O	164	171	between	between	IN	B-PP
B-Cell	172	183	endothelial	endothelial	JJ	B-NP
I-Cell	184	189	cells	cell	NNS	I-NP
O	190	193	and	and	CC	O
B-Cell	194	203	pericytes	pericyte	NNS	B-NP
O	203	204	.	.	.	O

O	205	216	Commonality	Commonality	NNP	B-NP
O	217	223	exists	exist	VBZ	B-VP
O	224	226	in	in	IN	B-PP
O	227	230	the	the	DT	B-NP
O	231	240	processes	process	NNS	I-NP
O	241	249	involved	involve	VBN	B-VP
O	250	252	in	in	IN	B-PP
B-Multi-tissue_structure	253	264	vasculature	vasculature	JJ	B-NP
O	265	276	development	development	NN	I-NP
O	277	284	between	between	IN	B-PP
B-Tissue	285	292	tissues	tissue	NNS	B-NP
O	293	300	whether	whether	IN	B-SBAR
O	301	308	healthy	healthy	JJ	B-ADJP
O	309	311	or	or	CC	I-ADJP
O	312	320	diseased	diseased	JJ	I-ADJP
O	320	321	.	.	.	O

O	322	332	Endosialin	Endosialin	NN	B-NP
O	332	333	/	/	SYM	O
O	333	336	TEM	TEM	NN	B-NP
O	337	338	1	1	CD	I-NP
O	339	341	is	be	VBZ	B-VP
O	342	343	a	a	DT	B-NP
B-Cellular_component	344	348	cell	cell	NN	I-NP
I-Cellular_component	349	357	membrane	membrane	NN	I-NP
O	358	365	protein	protein	NN	I-NP
O	366	370	that	that	WDT	B-NP
O	371	373	is	be	VBZ	B-VP
O	374	383	expressed	express	VBN	I-VP
O	384	386	in	in	IN	B-PP
B-Multi-tissue_structure	387	392	blood	blood	NN	B-NP
I-Multi-tissue_structure	393	400	vessels	vessel	NNS	I-NP
O	401	407	during	during	IN	B-PP
O	408	421	embryogenesis	embryogenesis	NN	B-NP
O	422	425	and	and	CC	I-NP
O	426	439	tumorigenesis	tumorigenesis	NN	I-NP
O	440	443	but	but	CC	B-PP
O	444	447	not	not	RB	B-PP
O	448	450	in	in	IN	I-PP
O	451	457	normal	normal	JJ	B-NP
B-Multi-tissue_structure	458	464	mature	mature	JJ	I-NP
I-Multi-tissue_structure	465	472	vessels	vessel	NNS	I-NP
O	472	473	.	.	.	O

O	474	484	Antibodies	Antibody	NNS	B-NP
O	485	494	developed	develop	VBD	B-VP
O	495	497	to	to	TO	B-PP
O	498	503	human	human	JJ	B-NP
O	504	514	endosialin	endosialin	NN	I-NP
O	515	519	were	be	VBD	B-VP
O	520	524	used	use	VBN	I-VP
O	525	527	to	to	TO	B-VP
O	528	539	investigate	investigate	VB	I-VP
O	540	550	endosialin	endosialin	NN	B-NP
O	551	561	expression	expression	NN	B-NP
O	562	565	and	and	CC	O
O	566	574	function	function	NN	B-NP
O	575	577	in	in	IN	B-PP
O	578	583	human	human	JJ	B-NP
B-Cell	584	592	prenatal	prenatal	JJ	I-NP
I-Cell	593	598	brain	brain	NN	I-NP
I-Cell	599	608	pericytes	pericyte	NNS	I-NP
O	609	612	and	and	CC	I-NP
B-Cell	613	622	pericytes	pericyte	NNS	I-NP
O	623	631	residing	reside	VBG	B-VP
O	632	634	in	in	IN	B-PP
B-Cancer	635	641	tumors	tumor	NNS	B-NP
O	641	642	.	.	.	O

O	643	647	Anti	Anti	AFX	B-NP
O	647	648	-	-	HYPH	I-NP
O	648	658	endosialin	endosialin	NN	B-NP
O	659	662	was	be	VBD	B-VP
O	663	670	capable	capable	JJ	B-ADJP
O	671	673	of	of	IN	B-PP
O	674	684	preventing	prevent	VBG	B-VP
B-Tissue	685	693	pericyte	pericyte	NN	B-NP
I-Tissue	694	698	tube	tube	NN	I-NP
O	699	708	formation	formation	NN	I-NP
O	709	711	in	in	IN	B-PP
O	712	719	culture	culture	NN	B-NP
O	720	723	and	and	CC	O
O	724	733	inhibited	inhibit	VBD	B-VP
O	734	743	migration	migration	NN	B-NP
O	743	744	.	.	.	O

B-Cell	745	750	Brain	Brain	NN	B-NP
I-Cell	751	760	pericytes	pericyte	NNS	I-NP
O	761	763	in	in	IN	B-PP
O	764	771	culture	culture	NN	B-NP
O	772	775	had	have	VBD	B-VP
O	776	782	higher	high	JJR	B-NP
O	783	789	levels	level	NNS	I-NP
O	790	792	of	of	IN	B-PP
O	793	803	endosialin	endosialin	NN	B-NP
O	803	804	/	/	SYM	O
O	804	807	TEM	TEM	NN	B-NP
O	808	809	1	1	CD	I-NP
O	810	814	than	than	IN	B-PP
O	815	819	TEMs	TEM	NNS	B-NP
O	819	820	-	-	HYPH	O
O	820	821	2	2	CD	B-NP
O	821	822	,	,	,	O
O	823	824	-	-	HYPH	B-NP
O	824	825	3	3	CD	I-NP
O	825	826	,	,	,	O
O	827	828	-	-	HYPH	B-NP
O	828	829	4	4	CD	I-NP
O	829	830	,	,	,	O
O	831	832	-	-	HYPH	B-NP
O	832	833	5	5	CD	I-NP
O	833	834	,	,	,	O
O	835	836	-	-	HYPH	B-NP
O	836	837	7	7	CD	I-NP
O	837	838	,	,	,	O
O	839	842	and	and	CC	O
O	843	844	-	-	SYM	B-NP
O	844	845	8	8	CD	I-NP
O	845	846	.	.	.	O

O	847	866	Immunocytochemistry	Immunocytochemistry	NN	B-NP
O	867	875	revealed	reveal	VBD	B-VP
O	876	880	that	that	IN	B-SBAR
O	881	891	endosialin	endosialin	NN	B-NP
O	892	895	was	be	VBD	B-VP
O	896	903	present	present	JJ	B-ADJP
O	904	906	in	in	IN	B-PP
O	907	910	the	the	DT	B-NP
B-Organism_substance	911	922	cytoplasmic	cytoplasmic	JJ	I-NP
I-Organism_substance	923	927	body	body	NN	I-NP
O	928	931	and	and	CC	B-PP
O	932	934	in	in	IN	B-PP
O	935	938	the	the	DT	B-NP
O	939	948	elongated	elongate	VBN	I-NP
O	949	959	extensions	extension	NNS	I-NP
O	960	969	essential	essential	JJ	B-ADJP
O	970	972	to	to	TO	B-PP
B-Cell	973	981	pericyte	pericyte	NN	B-NP
O	982	990	function	function	NN	I-NP
O	990	991	.	.	.	O

O	992	1002	Transgenic	Transgenic	JJ	B-NP
O	1003	1007	mice	mouse	NNS	I-NP
O	1008	1018	engineered	engineer	VBN	B-VP
O	1019	1021	to	to	TO	B-VP
O	1022	1029	express	express	VB	I-VP
O	1030	1035	human	human	JJ	B-NP
O	1036	1046	endosialin	endosialin	NN	I-NP
O	1047	1051	bred	breed	VBN	B-VP
O	1052	1054	on	on	IN	B-PP
O	1055	1057	an	an	DT	B-NP
O	1058	1075	immunocompromised	immunocompromised	JJ	I-NP
O	1076	1086	background	background	NN	I-NP
O	1087	1094	allowed	allow	VBD	B-VP
O	1095	1098	the	the	DT	B-NP
O	1099	1105	growth	growth	NN	I-NP
O	1106	1108	of	of	IN	B-PP
O	1109	1114	human	human	JJ	B-NP
B-Cancer	1115	1120	tumor	tumor	NN	I-NP
I-Cancer	1121	1131	xenografts	xenograft	NNS	I-NP
O	1131	1132	.	.	.	O

O	1133	1135	In	In	IN	B-PP
O	1136	1141	human	human	JJ	B-NP
B-Cancer	1142	1147	colon	colon	NN	I-NP
I-Cancer	1148	1157	carcinoma	carcinoma	NN	I-NP
I-Cancer	1158	1165	Colo205	Colo205	NN	I-NP
O	1166	1169	and	and	CC	I-NP
B-Cancer	1170	1174	HT29	HT29	NN	I-NP
I-Cancer	1175	1185	xenografts	xenograft	NNS	I-NP
O	1186	1191	grown	grow	VBN	B-VP
O	1192	1194	in	in	IN	B-PP
O	1195	1200	human	human	JJ	B-NP
O	1201	1211	endosialin	endosialin	NN	I-NP
O	1211	1212	-	-	HYPH	B-NP
O	1212	1222	transgenic	transgenic	JJ	I-NP
O	1223	1227	mice	mouse	NNS	I-NP
O	1227	1228	,	,	,	O
O	1229	1239	endosialin	endosialin	NN	B-NP
O	1240	1250	expression	expression	NN	I-NP
O	1251	1254	was	be	VBD	B-VP
O	1255	1262	largely	largely	RB	I-VP
O	1263	1271	confined	confine	VBN	I-VP
O	1272	1274	to	to	TO	B-PP
O	1275	1278	NG2	NG2	NN	B-NP
O	1278	1279	-	-	HYPH	O
O	1279	1289	expressing	express	VBG	B-VP
B-Cell	1290	1302	perivascular	perivascular	JJ	B-NP
I-Cell	1303	1308	cells	cell	NNS	I-NP
O	1309	1312	and	and	CC	O
O	1313	1316	not	not	RB	B-NP
B-Cell	1317	1321	CD31	CD31	NN	I-NP
I-Cell	1321	1322	-	-	HYPH	B-NP
I-Cell	1322	1330	positive	positive	JJ	I-NP
I-Cell	1331	1342	endothelial	endothelial	JJ	I-NP
I-Cell	1343	1348	cells	cell	NNS	I-NP
O	1348	1349	.	.	.	O

O	1350	1357	Similar	Similar	JJ	B-NP
O	1358	1365	methods	method	NNS	I-NP
O	1366	1373	applied	apply	VBN	B-VP
O	1374	1376	to	to	TO	B-PP
O	1377	1382	human	human	JJ	B-NP
B-Cancer	1383	1390	ovarian	ovarian	JJ	I-NP
O	1391	1394	and	and	CC	I-NP
B-Cancer	1395	1400	colon	colon	NN	I-NP
I-Cancer	1401	1407	tumors	tumor	NNS	I-NP
O	1408	1417	confirmed	confirm	VBD	B-VP
O	1418	1428	endosialin	endosialin	NN	B-NP
O	1429	1439	expression	expression	NN	I-NP
O	1440	1442	by	by	IN	B-PP
B-Cell	1443	1452	pericytes	pericyte	NNS	B-NP
O	1452	1453	.	.	.	O

O	1454	1457	The	The	DT	B-NP
O	1458	1462	data	datum	NNS	I-NP
O	1463	1471	indicate	indicate	VBP	B-VP
O	1472	1476	that	that	IN	B-SBAR
O	1477	1487	endosialin	endosialin	NN	B-NP
O	1488	1490	is	be	VBZ	B-VP
O	1491	1499	strongly	strongly	RB	I-VP
O	1500	1509	expressed	express	VBN	I-VP
O	1510	1512	by	by	IN	B-PP
B-Cell	1513	1522	pericytes	pericyte	NNS	B-NP
O	1523	1529	during	during	IN	B-PP
O	1530	1537	periods	period	NNS	B-NP
O	1538	1540	of	of	IN	B-PP
O	1541	1547	active	active	JJ	B-NP
O	1548	1560	angiogenesis	angiogenesis	NN	I-NP
O	1561	1567	during	during	IN	B-PP
B-Developing_anatomical_structure	1568	1577	embryonic	embryonic	JJ	B-NP
O	1578	1581	and	and	CC	I-NP
B-Cancer	1582	1587	tumor	tumor	NN	I-NP
O	1588	1599	development	development	NN	I-NP
O	1599	1600	.	.	.	O

O	1601	1605	Anti	Anti	AFX	B-NP
O	1605	1606	-	-	HYPH	I-NP
O	1606	1616	endosialin	endosialin	NN	I-NP
O	1617	1627	antibodies	antibody	NNS	I-NP
O	1628	1631	may	may	MD	B-VP
O	1632	1636	have	have	VB	I-VP
O	1637	1642	value	value	NN	B-NP
O	1643	1645	in	in	IN	B-PP
O	1646	1657	identifying	identify	VBG	B-VP
B-Multi-tissue_structure	1658	1669	vasculature	vasculature	NN	B-NP
O	1670	1672	in	in	IN	B-PP
B-Tissue	1673	1682	malignant	malignant	JJ	B-NP
I-Tissue	1683	1690	tissues	tissue	NNS	I-NP
O	1690	1691	.	.	.	O

O	1692	1696	With	With	IN	B-PP
O	1697	1700	the	the	DT	B-NP
O	1701	1712	appropriate	appropriate	JJ	I-NP
O	1713	1718	agent	agent	NN	I-NP
O	1718	1719	,	,	,	O
O	1720	1729	targeting	target	VBG	B-VP
O	1730	1740	endosialin	endosialin	NN	B-NP
O	1741	1744	may	may	MD	B-VP
O	1745	1754	interfere	interfere	VB	I-VP
O	1755	1759	with	with	IN	B-PP
B-Multi-tissue_structure	1760	1765	blood	blood	NN	B-NP
I-Multi-tissue_structure	1766	1772	vessel	vessel	NN	I-NP
O	1773	1779	growth	growth	NN	I-NP
O	1780	1786	during	during	IN	B-PP
B-Cancer	1787	1792	tumor	tumor	NN	B-NP
O	1793	1804	development	development	NN	I-NP
O	1804	1805	.	.	.	O

